MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure

Current Opinion in Cell Biology

Volumn 31, Issue , 2014, Pages 98-105

  Boccaccio, Carla ^a,b   Comoglio, Paolo M ^a,b  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL HETEROGENEITY; CELL PROLIFERATION; CLONAL EVOLUTION; GENE EXPRESSION; HUMAN; INHERITANCE; MET ONCOGENE; NEOPLASM; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY;

MET PROTEIN, HUMAN; SCATTER FACTOR RECEPTOR;

ANIMALS; CLONAL EVOLUTION; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 84925223695     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2014.09.008     Document Type: Review

References (75)

1. Scheel C., Onder T., Karnoub A., Weinberg R.A. Adaptation versus selection: the origins of metastatic behavior. Cancer Res 2007, 67:11476-11479.
2. Trusolino L., Comoglio P.M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002, 2:289-300.
3. Boccaccio C., Comoglio P.M. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006, 6:637-645.
4. Trusolino L., Bertotti A., Comoglio P.M. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010, 11:834-848.
5. Christofori G. New signals from the invasive front. Nature 2006, 441:444-450.
6. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119:1420-1428.
7. Comoglio P.M., Giordano S., Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008, 7:504-516.
8. Turke A.B., Zejnullahu K., Wu Y.L., Song Y., Dias-Santagata D., Lifshits D.E., Toschi L., Rogers A., Mok T., Sequist L., et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
9. Bardelli A., Corso S., Bertotti A., Hobor S., Valtorta E., Siravegna G., Sartore-Bianchi A., Scala E., Cassingena A., Zecchin D., et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013, 3:658-673.
10. Gherardi E., Birchmeier W., Birchmeier C., Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012, 12:89-103.
11. Bladt F., Riethmacher D., Isenmann S., Aguzzi A., Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995, 376:768-771.
12. Maina F., Casagranda F., Audero E., Simeone A., Comoglio P.M., Klein R., Ponzetto C. Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. Cell 1996, 87:531-542.
13. Chmielowiec J., Borowiak M., Morkel M., Stradal T., Munz B., Werner S., Wehland J., Birchmeier C., Birchmeier W. c-Met is essential for wound healing in the skin. J Cell Biol 2007, 177:151-162.
14. Gurtner G.C., Werner S., Barrandon Y., Longaker M.T. Wound repair and regeneration. Nature 2008, 453:314-321.
15. Stella G.M., Benvenuti S., Gramaglia D., Scarpa A., Tomezzoli A., Cassoni P., Senetta R., Venesio T., Pozzi E., Bardelli A., Comoglio P.M. MET mutations in cancers of unknown primary origin (CUPs). Hum Mutat 2011, 32:44-50.
16. Boccaccio C., Comoglio P.M. The MET oncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic target. Cancer Res 2013, 73:3193-3199.
17. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
18. Yano S., Wang W., Li Q., Matsumoto K., Sakurama H., Nakamura T., Ogino H., Kakiuchi S., Hanibuchi M., Nishioka Y., et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008, 68:9479-9487.
19. Liska D., Chen C.T., Bachleitner-Hofmann T., Christensen J.G., Weiser M.R. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res 2011, 17:472-482.
20. Troiani T.T., Martinelli E., Napolitano S., Vitagliano D., Ciuffreda L.P., Costantino S., Morgillo F., Capasso A., Sforza V., Nappi A.A., et al. Increased TGF-alpha as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clin Cancer Res 2013, 19:6751-6765.
21. Straussman R., Morikawa T., Shee K., Barzily-Rokni M., Qian Z.R., Du J., Davis A., Mongare M.M., Gould J., Frederick D.T., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
22. Wilson T.R., Fridlyand J., Yan Y., Penuel E., Burton L., Chan E., Peng J., Lin E., Wang Y., Sosman J., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487:505-509.
23. Harbinski F., Craig V.J., Sanghavi S., Jeffery D., Liu L., Sheppard K.A., Wagner S., Stamm C., Buness A., Chatenay-Rivauday C., et al. Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discov 2012, 2:948-959.
24. Pastrana E., Silva-Vargas V., Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 2011, 8:486-498.
25. Luraghi P., Reato G., Cipriano E., Sassi F., Orzan F., Bigatto V., De Bacco F., Menietti E., Han M., Rideout W.M., et al. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res 2014, 74:1857-1869.
26. Arteaga C.L., Engelman J.A., Receptors E.R.B.B From oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014, 25:282-303.
27. Boccaccio C., Luraghi P., Comoglio P.M. MET-mediated resistance to EGFR inhibitors: an old liaison rooted in colorectal cancer stem cells. Cancer Res 2014.
28. Gusenbauer S., Vlaicu P., Ullrich A. HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene 2013, 32:3846-3856.
29. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
30. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., Chitale D., Motoi N., Szoke J., Broderick S., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007, 104:20932-20937.
31. Burrell R.A., McGranahan N., Bartek J., Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013, 501:338-345.
32. Snuderl M., Fazlollahi L., Le L.P., Nitta M., Zhelyazkova B.H., Davidson C.J., Akhavanfard S., Cahill D.P., Aldape K.D., Betensky R.A., et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011, 20:810-817.
33. Paulson A.K., Linklater E.S., Berghuis B.D., App C.A., Oostendorp L.D., Paulson J.E., Pettinga J.E., Melnik M.K., Vande Woude G.F., Graveel C.R. MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance. Mol Cancer Res 2013, 11:1112-1121.
34. De Bacco F., Luraghi P., Medico E., Reato G., Girolami F., Perera T., Gabriele P., Comoglio P.M., Boccaccio C. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst 2011, 103:645-661.
35. Medova M., Aebersold D.M., Zimmer Y. MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks. Int J Cancer 2012, 130:728-734.
36. Hwang C.I., Matoso A., Corney D.C., Flesken-Nikitin A., Korner S., Wang W., Boccaccio C., Thorgeirsson S.S., Comoglio P.M., Hermeking H., Nikitin A.Y. Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci USA 2011, 108:14240-14245.
37. Muller P.A., Trinidad A.G., Timpson P., Morton J.P., Zanivan S., van den Berghe P.V., Nixon C., Karim S.A., Caswell P.T., Noll J.E.J.E., et al. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene 2013, 32:1252-1265.
38. Joffre C., Barrow R., Menard L., Calleja V., Hart I.R., Kermorgant S. A direct role for Met endocytosis in tumorigenesis. Nat Cell Biol 2011, 13:827-837.
39. Sullivan K.D., Padilla-Just N., Henry R.E., Porter C.C., Kim J., Tentler J.J., Eckhardt S.G., Tan A.C., DeGregori A.C.J., Espinosa J.M. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nat Chem Biol 2012, 8:646-654.
40. Camacho C.V., Todorova P.K., Hardebeck M.C., Tomimatsu N., Gil Del Alcazar C.R., Ilcheva M., Mukherjee B., McEllin B., Vemireddy V., Hatanpaa K., et al. DNA double-strand breaks cooperate with loss of Ink4 and Arf tumor suppressors to generate glioblastomas with frequent Met amplification. Oncogene 2014.
41. Ebos J.M., Kerbel R.S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011, 8:210-221.
42. de Groot J.F., Fuller G., Kumar A.J., Piao Y., Eterovic K., Ji Y., Conrad C.A. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010, 12:233-242.
43. Sennino B., McDonald.D.M. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 2012, 12:699-709.
44. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361.
45. You W.K., Sennino B.B., Williamson C.W., Falcon B., Hashizume H., Yao L.C., Aftab D.T., McDonald.D.M. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 2011, 71:4758-4768.
46. Sennino B., Ishiguro-Oonuma T., Wei Y., Naylor R.M., Williamson C.W., Bhagwandin V., Tabruyn S.P., You W.K., Chapman H.A., Christensen J.G., et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012, 2:270-287.
47. Sennino B., Ishiguro-Oonuma T., Schriver B.J., Christensen J.G., McDonald D.M. Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res 2013, 73:3692-3703.
48. Cooke V.G., LeBleu V.S., Keskin D., Khan Z., O'Connell J.T., Teng Y., Duncan M.B., Xie L., Maeda G., Vong S., et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012, 21:66-81.
49. Lu K.V., Chang J.P., Parachoniak C.A., Pandika M.M., Aghi M.K., Meyronet D., Isachenko N., Fouse S.D., Phillips J.J., Cheresh D.A., et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012, 22:21-35.
50. Yao H.P., Zhou Y.Q., Zhang R., Wang M.H. MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nat Rev Cancer 2013, 13:466-481.
51. Benvenuti S., Lazzari L., Arnesano A., Li Chiavi G., Gentile A., Comoglio P.M. Ron kinase transphosphorylation sustains MET oncogene addiction. Cancer Res 2011, 71:1945-1955.
52. Gentile A., Lazzari L., Benvenuti S., Trusolino L., Comoglio P.M. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res 2011, 71:3132-3141.
53. Gentile A., Lazzari L., Benvenuti S., Trusolino L., Comoglio P.M. The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells. Int J Cancer 2014.
54. Muharram G., Sahgal P., Korpela T., De Franceschi N., Kaukonen R., Clark K., Tulasne D., Carpen O., Ivaska J. Tensin-4-dependent MET stabilization is essential for survival and proliferation in carcinoma cells. Dev Cell 2014, 29:421-436.
55. Boccaccio C., Ando' M., Tamagnone L., Bardelli A., Michieli P., Battistini C., Comoglio P.M. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 1998, 391:285-288.
56. Lai A.Z., Cory S., Zhao H., Gigoux M., Monast A., Guiot M.C., Huang S., Tofigh A., Thompson C., Naujokas M., et al. Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer. Sci Signal 2014, 7:ra38.
57. Van Schaeybroeck S., Kalimutho M., Dunne P.D., Carson R., Allen W., Jithesh P.V., Redmond K.L., Sasazuki T., Shirasawa S., Blayney J., et al. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell Rep 2014, 7:1940-1955.
58. Schmidt C., Bladt F., Goedecke S., Brinkmann V., Zschiesche W., Sharpe M., Gherardi E., Birchmeier C. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995, 373:699-702.
59. Duncan A.W., Dorrell C., Grompe M. Stem cells and liver regeneration. Gastroenterology 2009, 137:466-481.
60. Ishikawa T., Factor V.M., Marquardt J.U., Raggi C., Seo D., Kitade M., Conner E.A., Thorgeirsson S.S. Hepatocyte growth factor/c-met signaling is required for stem-cell-mediated liver regeneration in mice. Hepatology 2012, 55:1215-1226.
61. Kitade M., Factor V.M., Andersen J.B., Tomokuni A., Kaji K., Akita H., Holczbauer A., Seo D., Marquardt J.U., Conner E.A., et al. Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling. Genes Dev 2013, 27:1706-1717.
62. Gastaldi S., Sassi F., Accornero P., Torti D., Galimi F., Migliardi G., Molyneux G., Perera T., Comoglio P.M., Boccaccio C., et al. Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. Oncogene 2013, 32:1428-1440.
63. Molyneux G., Geyer F.C., Magnay F.A., McCarthy A., Kendrick H., Natrajan R., Mackay A., Grigoriadis A., Tutt A., Ashworth A., et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010, 7:403-417.
64. Charafe-Jauffret E., Ginestier C., Monville F., Finetti P., Adelaide J., Cervera N., Fekairi S., Xerri L., Jacquemier J., Birnbaum D., Bertucci F.F. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006, 25:2273-2284.
65. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
66. Nicoleau C., Benzakour O., Agasse F., Thiriet N., Petit J., Prestoz L., Roger M., Jaber M., Coronas V. Endogenous hepatocyte growth factor is a niche signal for subventricular zone neural stem cell amplification and self-renewal. Stem Cells 2009, 27:408-419.
67. Chen J., McKay R.M., Parada L.F. Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell 2012, 149:36-47.
68. Joo K.M., Jin J., Kim E., Ho K.K., Kim Y., Gu K.B., Kang Y.J., Lathia J.D., Cheong K.H., Song P.H., et al. MET signaling regulates glioblastoma stem cells. Cancer Res 2012, 72:3828-3838.
69. Li Y., Li A., Glas M., Lal B., Ying M., Sang Y., Xia S., Trageser D., Guerrero-Cazares H., Eberhart C.G., et al. c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci USA 2011, 108:9951-9956.
70. De Bacco F., Casanova E., Medico E., Pellegatta S., Orzan F., Albano R., Luraghi P., Reato G., D'Ambrosio A., Porrati P., et al. The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res 2012, 72:4537-4550.
71. Liu X., Sun H., Qi J., Wang L., He S., Liu J., Feng C., Chen C., Li W., Guo Y., et al. Sequential introduction of reprogramming factors reveals a time-sensitive requirement for individual factors and a sequential EMT-MET mechanism for optimal reprogramming. Nat Cell Biol 2013, 15:829-838.
72. Lai J.K., Wu H.C., Shen Y.C., Hsieh H.Y., Yang S.Y., Chang C.C. Kruppel-like factor 4 is involved in cell scattering induced by hepatocyte growth factor. J Cell Sci 2012, 125:4853-4864.
73. Phillips H.S., Kharbanda S., Chen R., Forrest W.F., Soriano R.H., Wu T.D., Misra A., Nigro J.M., Colman H., Soroceanu L., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173.
74. Cooper C.S., Park M., Blair D.G., Tainsky M.A., Huebner K., Croce C.M., Vande Woude G.F. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984, 311:29-33.
75. Giordano S., Ponzetto C., Di Renzo M.F., Cooper C.S., Comoglio P.M. Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 1989, 339:155-156.